Dallah Healthcare Co. announces its Interim Financial Results for the Period Ending on 2021-03-31 ( Three Months )

02 May 2021 08:05 AM

DALLAH HEALTH 4004 6.01% 165.80 9.40

Element List	Current Quarter	Similar quarter for previous year	%Change	Previous Quarter	% Change
Sales/Revenue	494.7	314.6	57.247	405.3	22.057
Gross Profit (Loss)	176.8	105.8	67.107	143.6	23.119
Operational Profit (Loss)	72.9	26.4	176.136	40.3	80.893
Net Profit (Loss) after Zakat and Tax	54.6	19.2	184.375	20.1	171.641
Total Comprehensive Income	54.6	19.2	184.375	26.7	104.494
All figures are in (Millions) Saudi Arabia, Riyals

Element List	Current Period	Similar period for previous year	%Change
Total Share Holders Equity (after Deducting Minority Equity)	1,881.9	1,491.5	26.174
Profit (Loss) per Share	0.58	0.23
All figures are in (Millions) Saudi Arabia, Riyals

Element List	Explanation
The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is	Increase in net profit for the current quarter compared to the same quarter of the last year is due to: 1- Increase operating revenues as a result of growing numbers of inpatients and outpatients in Dallah Hospitals. 2- Increase in operating level of Dallah Namar Hospital compare to the same quarter of last year. 3- increase in the group’s revenues and result of operations as a result of acquisitions of majority of shares of Cares Shield Holding Co and Makkah Medical Center Co.
The reason of the increase (decrease) in the net profit during the current quarter compared to the previous period of the current year is	Increase in net income during the current quarter compared to last quarter is due to: 1- Increase of Dallah Namar Hospital’s revenues resulted from the escalating operations levels. 2- Increase in number of patients of Dallah Alnakheel during the current quarter compared to the last quarter due to return back to the normal operating levels after application of curfew procedures during the second quarter. 3- Gains in instruments at fair value by the company’s investments. 4- Dividends from investments at fair value.
Statement of the type of external auditor's report	Unmodified conclusion
Reclassification of Comparison Items	Elements and notes of the comparatives Interim Condensed Consolidated Financial Statements have been reclassified and regrouped to meet with the International Financial Reporting Standards (IFRS) that are endorsed in the Kingdom of Saudi Arabia. During the current period, there has been remeasurement of some estimations and judgements that the company is basing on in it the process accompanying the preparing the interim financial statements as a result of Coronavirus (COVID-19). For more info, please refer to Note 12 in the notes to the financial statements (The effect of Coronavirus (COVID-19) on the condensed consolidated financial statements) the period ended 31 March 2021.
Additional Information	Earnings-per-share is calculated based on the weighted average number of standing shares amounted to 90,000,000 shares for the three ended 31 March 2021. (compared to 85,512,000 shares for the three months 31 March 2021) The company issued 15 million shares on 13/09/2020 to increasing the company’s capital through distribution of free shares with a ratio of 20.0% to increase the number of outstanding shares from 75 million to 90 million shares. Number of treasury shares was excluded from the average shares outstanding which were traded out in November 2020. We would like to draw the attention to the shareholders that the interim condensed consolidated financial statements for the period ended 31 March 2021 will be available through the following link on the company 's Website after submitting them to the related authorities. http://www.dallahhealth.com/english/investors The company would like also to draw the attention of the financial analysts and investors to send their inquiries to the company’s email: [email protected] during 3 days from publishing of the financial statements.

Comments